Dendritic cell vaccination for patients with chronic myelogenous leukemia

Leukemia Research

Volumn 27, Issue 9, 2003, Pages 795-802

  Takahashi, Tsuyoshi ^a   Tanaka, Yuji ^b   Nieda, Mie ^c   Azuma, Takeshi ^d   Chiba, Shigeru ^a   Juji, Takeo ^c   Shibata, Yoichi ^a   Hirai, Hisamaru ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^c Japanese Red Central Blood Center   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

Author keywords

bcr abl; Chronic myelogenous leukemia; Clinical study; Dendritic cell; Vaccination

Indexed keywords

BCR ABL PROTEIN; PEPTIDE; VACCINE;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD CELL; CASE REPORT; CELLULAR IMMUNITY; CHRONIC MYELOID LEUKEMIA; DENDRITIC CELL; DRUG TOLERABILITY; FEVER; HUMAN; IMMUNOMODULATION; IMMUNOSTIMULATION; MALE; MONOCYTE; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME; TUMOR IMMUNITY; VACCINATION; VACCINATION REACTION;

EID: 0037865501     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(03)00011-0     Document Type: Article

References (24)

1. Hart D.N.J. Dendritic cells: unique leukocyte populations, which control the primary immune response. Blood. 90:1997;3245-3287.
2. Banchereau J., Steinmen R.M. Dendritic cells and the control of immunity. Nature. 392:1998;245-252.
3. Cella M., Sallusto F., Lanzavecchia A. Origin. Cur. Opin. Immunol. 9:1997;10-16.
4. Celluzzi C.M., Mayordomo J.I., Storkus W.J., Lotze M.T., Falo L.D. Jr. Peptide-pulsed dendritic cells induce antigen-specific, CTL-mediated protective tumor immunity. J. Exp. Med. 183:1996;283-287.
5. Porgador A., Snyder D., Gilboa E. Induction of antitumor immunity using bone marrow-generated dendritic cells. J. Immunol. 156:1996;2918-2926.
6. Zitvogel L., Mayordomo J.I., Tjandrawan T., DeLeo A.B., Clarke M.R., Lotze M.T.et al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J. Exp. Med. 183:1996;87-97.
7. Hsu F., Benike C., Fagnoni F., Liles T.M., Czerwiniski D., Taidi B.et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med. 2:1996;52-58.
8. Murphy G., Tjoa B., Ragde H., Kenny G., Boynton A. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A*0201-specific peptides from prostate-specific membrane antigen. Prostate. 29:1996;371-380.
9. Nestle F.O., Alijagic S., Gilliet M., Sun Y., Grabbe S., Dummer R.et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. 4:1998;328-332.
10. Wen Y.J., Ling M., Bailey-Wood R., Lim S.H. Idiotypic protein-pulsed adherent peripheral blood mononuclear cell-derived dendritic cells prime immune system in multiple myeloma. Clin. Cancer Res. 4:1998;957-962.
11. Faderl S., Talpaz M., Estrov Z., O'Brien S., Kurzrock R., Kantarjian H.M. Mechanisms of disease: the biology of chronic myeloid leukemia. N. Engl. J. Med. 341:1999;164-172.
12. bcr-abl protein by human T cells. Leukemia. 9:1995;1344-1348.
13. Boccia M., Korontsvit T., Mackinnon Xu Q., Yong Yang S., Sette A., Scheinberg D.A. Specific human cellular immunity to bcr-abl oncogene-derived peptides. Blood. 87:1996;3587-3592.
14. bcr-abl protein in patients with chronic myelogenous leukemia. J. Clin. Invest. 101:1998;2290-2296.
15. + T cells with cytotoxic activity against leukemic cells from patients with chronic myeloid leukemia. Blood. 91:1998;977-983.
16. Osman Y., Takahashi M., Zheng Z., Koike T., Toba K., Liu A.et al. Generation of bcr-abl specific cytotoxic T-lymphocytes by using of dendritic cells pulsed with bcr-abl (b3a2) peptide: its applicability for donor leukocyte transfusion in marrow grafted CML patients. Leukemia. 13:1999;166-174.
17. Choudhury A., Gajewski J., Liang J.C., Popat U., Claxton D.E., Kliche K.O.et al. Use of leukemic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia. Blood. 89:1997;1133-1142.
18. Muller L., Provenzani C., Faul C., Pawelec G. Recognition of chronic myelogenous leukaemia cells by autologous T lymphocytes primed in vitro against the patient's dendritic cells. Br. J. Haematol. 112:2001;740-748.
19. Pinilla-Ibarz J., Cathcart K., Korontsvit T., Soignet S., Bocchia M., Caggiano J.et al. Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses. Blood. 95:2000;1781-1787.
20. Fujii S., Shimizu K., Fujimoto K., Kiyokawa T., Shimomura T., Kinoshita M.et al. Analysis of a chronic myelogenous leukemia patient vaccinated with leukemic dendritic cells following autologous peripheral blood stem cell transplantation. Jpn. J. Cancer Res. 90:1999;1117-1129.
21. Thurner B., Haendle I., Roder C., Dieckmann D., Keikavoussi P., Jonuleit H.et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J. Exp. Med. 190:1999;1669-1678.
22. Baggers J., Ratzinger G., Young J. Dendritic cells as immunologic adjuvants for the treatment of cancer. J. Clin. Oncol. 18:2000;3879-3882.
23. Morse M.A., Coleman R.E., Akabani G., Niehaus N., Coleman D., Lyerly H.K. Migration of human dendritic cells after injection inpatients with metastatic malignancies. Cancer Res. 59:1999;56-58.
24. Druker B.J., Talpaz M., Resta D.J., Peng B., Buchdunger E., Ford J.M.et al. Efficacy and safety of a specific inhibitor of the bcr-abl tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344:2001;1031-1037.